12 results about "Adenomyosis" patented technology

The present invention relates to an integrated diagnostic system for deep endometriosis and / or adenomyosis, comprising three interconnected platforms and a method for analysing images generated by algorithms. The first platform combines patient medical history data with transvaginal ultrasound and / or pelvic magnetic resonance images, using algorithms to generate clear and detailed images of lesions. The method for analysing these images includes pre-processing, merging of clinical data and images, lesion identification, and comparison with a clinical database, resulting in a visual and descriptive analysis of the lesions, facilitating early and assertive diagnosis. The second platform is a communication network among specialist physicians, who perform a second reading of the images and issue a validated final report. The third platform is educational, offering personalised training and mentoring for imaging physicians using the images generated by the first platform to improve their diagnostic skills. The system reduces diagnostic time, increases accuracy, and contributes to the continuous professional development of physicians involved in the management of deep endometriosis and / or adenomyosis.

This invention relates to methods for treating endometriosis and providing effective contraception. Specifically, it relates to drospirenone in methods for treating endometriosis, endometriosis-associated pelvic pain (EAPP), and / or dysmenorrhea, the method comprising administering drospirenone in a biphasic regimen. The invention also relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, and to pharmaceutical compositions and devices comprising drospirenone administered in such a biphasic regimen.

In an illustrative embodiment, methods and systems for treating fertility conditions in women diagnosed with polycystic ovary syndrome (PCOS), endometriosis, and / or adenomyosis using electrical neurostimulation include delivering neurostimulation therapy via electrical or mechanical stimulation elements, the neurostimulation therapy including applying first neurostimulation pulses using electrical neurostimulation or mechanical neurostimulation at one or more first regions of skin of the subject to directly and / or indirectly activate a nucleus tractus solitary (NTS) and / or a trigeminal cervical complex (TCC) to activate anti-inflammatory pathways, and applying second neurostimulation pulses using electrical neurostimulation or mechanical neurostimulation at one or more second regions of skin of the subject to directly and / or indirectly activate vagal neural fibers and / or trigeminal neural fibers, wherein the neurostimulation pulses are configured to increase a parasympathetic / sympathetic (P / S) ratio.

This invention discloses a medical endometriosis surgery guide, belonging to the field of medical device technology. It includes a base rod, an insertion rod, and a base. The insertion rod is connected to the bottom end of the outer wall of the base rod, and the base is connected to the top end of the outer wall of the base rod. The medical endometriosis surgery guide disclosed in this invention, through modular assembly and threaded connection design, allows for independent and quick replacement of components without the need to discard the entire instrument. The insertion rod, with its anti-slip texture, prevents the instrument from slipping during critical steps. A press-to-unlock, rotation-to-adjust, and spring-reset locking mechanism allows for quick and flexible angle adjustment during surgery, ensuring a secure lock after rotation without the risk of loosening. Furthermore, the adjustable angle is combined with the physiological curvature of the rectum, reducing the risk of tissue traction or puncture injury caused by forced instrument insertion.

The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, in subjects suffering from, for example, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids, to minimize changes in bone mineral density associated with such GnRH receptor antagonists.

The application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating adenomyosis and application thereof. The traditional Chinese medicine composition is prepared from raw medicinal materials in the following mass fractions: 20-45 parts of Astragalus membranaceus, 10-15 parts of Ramulus Cinnamomi, 10-15 parts of Angelica sinensis, 10-15 parts of Fried Semen Persicae, 6-9 parts of Rhei Radix et Rhizoma with liquor, 10-12 parts of Poria cocos, 6-9 parts of Eupolyphaga, 6-9 parts of Yunnan giant Himalayan lily, and 3-6 parts of Panax notoginseng powder. The clinical research results prove that the traditional Chinese medicine composition can effectively treat adenomyosis of yang deficiency and blood stasis type, improve symptoms such as dysmenorrhea, chronic pelvic pain, menorrhagia, prolonged menstrual period and the like of patients, and improve hemoglobin level, while avoiding obvious adverse reactions, and therefore has good practical application value.

Provided herein is a targeting molecule, wherein the targeting molecule binds to a surface molecule on an endometrial endothelial cell (EEC) in which expression of the surface molecule is upregulated.

The application provides application of hydroxysafflor yellow A in preparation of medicines for preventing, treating and / or relieving endometriosis, and belongs to the technical field of biological medicines. The application provides application of hydroxysafflor yellow A in preparation of medicines for preventing, treating and / or relieving endometriosis. Hydroxysafflor yellow A can inhibit migration and / or diffusion of endometriosis cyst, inhibit migration, invasion and abnormal planting of endometrial tissue and / or endometriosis cells outside the uterine cavity, relieve inflammatory reaction caused by endometriosis, and effectively curb lesion invasion and disease progression of endometriosis. As a main active component of safflower, hydroxysafflor yellow A provides a new direction for manufacturing new medicines for treating endometriosis by using safflower.

This invention relates to the field of ultrasound imaging diagnostic technology, and discloses a method and system for diagnosing adenomyosis based on multi-parameter ultrasound imaging of the cervix. The method utilizes a transvaginal probe to acquire two-dimensional grayscale, shear wave elasticity, and ultra-micro blood flow images of the cervix. An anatomical coordinate system is established based on the longitudinal axis of the cervical canal in the grayscale image, and multiple independent quantitative analysis sub-regions covering the internal os and mid-segment of the cervix are identified as measurement target areas within the cervical parenchyma. Young's modulus, reflecting tissue stiffness, and resistance index, reflecting microcirculatory resistance, are extracted from the elasticity and blood flow images, respectively. The extracted parameters are input into a multivariate logistic regression diagnostic model, and the probability value of disease risk is calculated based on weighted coefficients, outputting a classification conclusion. This invention overcomes the limitations of morphological diagnosis through a standardized target area localization strategy and multi-modal parameter joint modeling, achieving objective quantitative diagnosis of adenomyosis and improving the accuracy and repeatability of detection.

The utility model discloses a kind of cutting knives for adenomyosis uterine conservation U surgery, it is related to the technical field of medical devices, the utility model aims at solving the problem that healthy cells are easily damaged in adjusting blade tip position during uterine conservation U surgery process, the utility model includes cutter barrel, the bottom end of the cutter barrel is open, cutting knife body is coaxially sleeved in the cutter barrel, two vertical grooves are formed in the side wall of the cutter barrel, the top of two vertical grooves is communicated by ring groove, the outer wall of cutting knife body is connected with sliding cap by sliding block, the sliding block is slidingly connected in the vertical groove, and the sliding cap is arranged outside the cutter barrel.

This invention relates to an automatic classification method and system for adenomyosis based on multiplanar MRI images, belonging to the field of adenomyosis classification technology, and solving the problem of inaccurate classification in existing technologies. The method includes the following steps: segmenting multiplanar MRI images of different individuals using multiple trained segmentation models to extract the multiplanar uterine region of interest (ROI) for each individual; constructing a second training set based on the multiplanar uterine ROI and the corresponding adenomyosis classification for each individual; constructing a deep learning model for adenomyosis classification; training the deep learning model based on the second training set to obtain an adenomyosis classification model; inputting the multiplanar MRI images of the individual to be classified into the trained segmentation models to obtain the multiplanar uterine ROI for the individual to be classified; and inputting the multiplanar uterine ROI of the individual to be classified into the adenomyosis classification model to obtain the adenomyosis classification for the individual to be classified. This achieves accurate and efficient adenomyosis classification.

The present invention relates to new uses and methods of treatment. More specifically, the invention relates to new uses of histone deacetylase inhibitors (HDACI) such as valproic acid (VPA), for enhancing in vitro fertilization (IVF) in patients suffering with adenomyosis associated infertility.